The PIPE included common stock and pre-funded warrants

Davis Polk advised Oruka Therapeutics, Inc. in connection with its $180 million private placement of common stock and pre-funded warrants.

Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel biologics designed to set a new standard for the treatment of chronic skin diseases.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Paula Gergen and Erica F. Buonanno. The investment management team included counsel Sarah E. Kim and associates Rosina Curren and Uche I. Polanco. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post